Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Microbial Ecosystem Therapeutics 2 (MET-2) & Clostridioides difficile infection (CDI) (recurrent)

Navigation

Contents

Non-randomized clinical trials

NCT02865616
MET-2 seems to be a safe, effective, and well-tolerated option for patients experiencing recurrent C difficile infections (1)

References

(1) Kao et al. 2021 Lancet Gastroenterol Hepatol 6(4): 282-291

see also:
Clostridioides difficile infection (CDI) (recurrent) & Drugs/Treatments
Fecal Microbiota Transplantation (FMT) & Clostridioides difficile infection (CDI) (recurrent)
Microbiome-based therapeutics & Clostridioides difficile infection (CDI) (recurrent)

References (Sources)

The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial
Kao et al. 2021 Lancet Gastroenterol Hepatol 6(4): 282-291
Update on microbiota-derived therapies for recurrent Clostridioides difficile infections
Benech et al. 2024 Clinical Microbiology and Infection 30: 462-468
Review

AI Chat

11/5/2026

Chat with our artificial intelligence: